Abstract
Ischemic heart disease including myocardial infarction develops on the basis of several risk-factors and comorbidities such as obesity, diabetes, hypertension, and hypercholesterolemia. Ischemic heart disease is the leading cause of mortality worldwide, therefore, identification of novel drug targets for cardioprotection is of great importance. Ischemic preconditioning, postconditioning, and remote conditioning trigger endogenous cardioprotective mechanisms that render the heart more resistant to lethal ischemic-reperfusion injury. However, major cardiovascular co-morbidities such as hyperlipidemia, diabetes, and their co-medications interfere with these cardioprotective mechanisms thereby limiting the efficacy of cardioprotective ischemic conditioning maneuvers. Ischemia reperfusion injury and cardioprotection by conditioning have been shown to affect global myocardial gene expression profile at the transcript level. Further understanding and the comprehensive analysis of the cardioprotective gene expression fingerprint in normal, protected, and in comorbid conditions may lead to identification of novel molecular targets for cardioprotection.
Keywords: Microarray, microRNA, miRNA, mRNA, postconditioning, preconditioning, proteomics, risk factors, sequencing, system biology, transcriptomics.
Current Drug Targets
Title:Functional Genomics of Cardioprotection by Ischemic Conditioning and the Influence of Comorbid Conditions: Implications in Target Identification
Volume: 16 Issue: 8
Author(s): Zoltan V. Varga, Zoltan Giricz, Peter Bencsik, Rosalinda Madonna, Mariann Gyongyosi, Rainer Schulz, Manuel Mayr, Thomas Thum, Laszlo G. Puskas and Peter Ferdinandy
Affiliation:
Keywords: Microarray, microRNA, miRNA, mRNA, postconditioning, preconditioning, proteomics, risk factors, sequencing, system biology, transcriptomics.
Abstract: Ischemic heart disease including myocardial infarction develops on the basis of several risk-factors and comorbidities such as obesity, diabetes, hypertension, and hypercholesterolemia. Ischemic heart disease is the leading cause of mortality worldwide, therefore, identification of novel drug targets for cardioprotection is of great importance. Ischemic preconditioning, postconditioning, and remote conditioning trigger endogenous cardioprotective mechanisms that render the heart more resistant to lethal ischemic-reperfusion injury. However, major cardiovascular co-morbidities such as hyperlipidemia, diabetes, and their co-medications interfere with these cardioprotective mechanisms thereby limiting the efficacy of cardioprotective ischemic conditioning maneuvers. Ischemia reperfusion injury and cardioprotection by conditioning have been shown to affect global myocardial gene expression profile at the transcript level. Further understanding and the comprehensive analysis of the cardioprotective gene expression fingerprint in normal, protected, and in comorbid conditions may lead to identification of novel molecular targets for cardioprotection.
Export Options
About this article
Cite this article as:
Varga V. Zoltan, Giricz Zoltan, Bencsik Peter, Madonna Rosalinda, Gyongyosi Mariann, Schulz Rainer, Mayr Manuel, Thum Thomas, Puskas G. Laszlo and Ferdinandy Peter, Functional Genomics of Cardioprotection by Ischemic Conditioning and the Influence of Comorbid Conditions: Implications in Target Identification, Current Drug Targets 2015; 16 (8) . https://dx.doi.org/10.2174/1389450116666150427154203
DOI https://dx.doi.org/10.2174/1389450116666150427154203 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Are Antipsychotics Useful in the Treatment of Anorexia Nervosa? A Review of the Literature
Current Psychopharmacology Microarray: An Approach for Current Drug Targets
Current Drug Metabolism Bromodomain-Containing Protein 4: A Druggable Target
Current Drug Targets Towards Optimal Heart Failure Care: Couples-Oriented Strategies to Improve Patient Adherence and Health Outcomes
Current Cardiology Reviews MicroRNAs in Peripheral Artery Disease
Current Topics in Medicinal Chemistry Mechanisms of the Beneficial Actions of Ischemic Preconditioning on Subcellular Remodeling in Ischemic-Reperfused Heart
Current Cardiology Reviews Cellular Cardiomyoplasty – Challenges of a New Era
Current Tissue Engineering (Discontinued) COVID-19: A Great Mime or a Trigger Event of Autoimmune Manifestations?
Current Rheumatology Reviews The Right Ventricle: Biologic Insights and Response to Disease: Updated
Current Cardiology Reviews Potential Strategies for Minimizing Mechanism-Based Inhibition of Cytochrome P450 3A4
Current Pharmaceutical Design Dynamic Role of Macrophage Sub Types on Development of Atherosclerosis and Potential Use of Herbal Immunomodulators as Imminent Therapeutic Strategy
Cardiovascular & Hematological Agents in Medicinal Chemistry Clinical Applications of Positron Emission Tomography (PET) Imaging in Medicine: Oncology, Brain Diseases and Cardiology
Current Radiopharmaceuticals Smoking and Cognition
Current Drug Abuse Reviews Pharmacotherapy of Abdominal Aortic Aneurysms
Current Vascular Pharmacology Resveratrol as a Supplemental Therapeutic in Cardiovascular and Metabolic Syndromes: A Critical Review
Current Nutrition & Food Science Current Advances in the Treatment of Parkinsons Disease with Stem Cells
Current Neurovascular Research Editorial [ Advanced Glycation End Products (AGEs) and their Receptor (RAGE) in Health and Disease Executive Editor: Sho-ichi Yamagishi ]
Current Pharmaceutical Design Recent Patents on PCSK9: A New Target for Treating Hypercholesterolemia
Recent Patents on DNA & Gene Sequences Impact of CYP2D6 Genetic Variation on the Response of the Cardiovascular Patient to Carvedilol and Metoprolol
Current Drug Metabolism The Role of Inflammatory Response in Stroke Associated Programmed Cell Death
Current Neuropharmacology